Arrhythmia Research Technologies, Inc. Appoints Michael Gunter as
FITCHBURG, MA -- (Marketwire) -- 10/30/12 -- Arrhythmia Research
Technology, Inc. ("ART" or the "Company") (NYSE MKT: HRT) today
announced the appointment of Michael S. Gunter, a director, as
interim Chief Executive Officer upon the resignation of James E.
Rouse as the Company's Chief Executive Officer and as a member of its
Board of Directors effective October 26, 2012.
"It has been a pleasure to have worked at ART and Micron Products
these past sixteen years. After much thought, I have decided to take
some time to pursue a new path in my career. I wish ART and its
employees much success in the future," said Mr. Rouse.
Mr. E.P. Marinos, Chairman of the Board of Directors, said: "The
Board and I are grateful to Mr. Rouse for his leadership and
integrity in guiding ART and its operating subsidiary, Micron
Products, Inc., over the past sixteen years. We wish him all the best
with the next stage in his career. We are confident that Mr. Gunter's
familiarity with the Company's business from his service over the
past year and more as a director as well as his previous eight years
experience at Primo Water Corp., most recently as Sr. Vice President,
will help to facilitate a smooth transition."
Mr. Gunter said, "I look forward to working with the management team
and dedicated employees with a focus on returning the Company to
profitability in the near term as the Company concentrates its
efforts on its core manufacturing competencies."
About Arrhythmia Research Technology, Inc.
The Company through its wholly-owned subsidiary, Micron Products,
Inc., manufactures silver plated and non-silver plated conductive
resin sensors and distributes metal snaps used in the manufacture of
disposable ECG, EEG, EMS and TENS electrodes. Micron's MIT division
provides end-to-end product life cycle management through a
comprehensive portfolio of value-added services such as design,
engineering, prototyping, manufacturing, machining, assembly and
packaging. MIT manufactures custom injection molded products for
medical, electronic, industrial and consumer applications, and
provides high end mold design, manufacturing and precision machining
for various industries. The Company's pr
oducts also include a
customizable proprietary signal-averaging electrocardiography (SAECG)
software used in the detection of potentially lethal heart
arrhythmias and that is reconfigurable for a variety of hardware
For more information please check our websites:
Forward-looking statements made herein are based on current
expectations of the Company that involve a number of risks and
uncertainties and should not be considered as guarantees of future
performance. The factors that could cause actual results to differ
materially include: our ability to maintain our current pricing model
and/or decrease our cost of sales; our ability to increase sales of
higher margin products and services; variations in the mix of
products sold; variability of customer delivery requirements; a
stable interest rate market and/or a stable currency rate environment
in the world, and specifically the countries where we are doing
business; continued availability of supplies or materials used in
manufacturing at competitive prices; volatility in commodity and
energy prices and our ability to offset higher costs with price
increases. More information about factors that potentially could
affect the Company's financial results is included in the Company's
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the year ended December 31, 2011.
David A. Garrison
Press spacebar to pause and continue. Press esc to stop.